Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Emerging formats for next-generation antibody drug conjugates.

Deonarain MP, Yahioglu G, Stamati I, Marklew J.

Expert Opin Drug Discov. 2015 May;10(5):463-81. doi: 10.1517/17460441.2015.1025049. Epub 2015 Mar 23. Review.

PMID:
25797303
2.

Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin.

Johdi NA, Harman R, Sanjuan I, Kousparou C, Courtenay-Luck N, Deonarain MP.

Protein Expr Purif. 2013 Mar;88(1):157-63. doi: 10.1016/j.pep.2012.12.002. Epub 2013 Jan 3.

PMID:
23291225
3.

Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.

Kousparou CA, Yiacoumi E, Deonarain MP, Epenetos AA.

BMC Cancer. 2012 Aug 3;12:338. doi: 10.1186/1471-2407-12-338.

4.

Glycoengineering approach to half-life extension of recombinant biotherapeutics.

Chen C, Constantinou A, Chester KA, Vyas B, Canis K, Haslam SM, Dell A, Epenetos AA, Deonarain MP.

Bioconjug Chem. 2012 Aug 15;23(8):1524-33. doi: 10.1021/bc200624a. Epub 2012 Jul 11.

PMID:
22681552
5.

Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro.

Stamati I, Kuimova MK, Lion M, Yahioglu G, Phillips D, Deonarain MP.

Photochem Photobiol Sci. 2010 Jul 30;9(7):1033-41. doi: 10.1039/c0pp00038h. Epub 2010 Jun 8.

PMID:
20532306
6.

Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding.

Scott N, Qazi O, Wright MJ, Fairweather NF, Deonarain MP.

Mol Immunol. 2010 Jun;47(10):1931-41. doi: 10.1016/j.molimm.2010.02.020. Epub 2010 Apr 22.

7.

Modulating the pharmacokinetics of therapeutic antibodies.

Constantinou A, Chen C, Deonarain MP.

Biotechnol Lett. 2010 May;32(5):609-22. doi: 10.1007/s10529-010-0214-z. Epub 2010 Feb 4. Review.

PMID:
20131077
8.

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

Deonarain MP, Kousparou CA, Epenetos AA.

MAbs. 2009 Jan-Feb;1(1):12-25. Review.

9.

Natural killer cell signal integration balances synapse symmetry and migration.

Culley FJ, Johnson M, Evans JH, Kumar S, Crilly R, Casasbuenas J, Schnyder T, Mehrabi M, Deonarain MP, Ushakov DS, Braud V, Roth G, Brock R, Köhler K, Davis DM.

PLoS Biol. 2009 Jul;7(7):e1000159. doi: 10.1371/journal.pbio.1000159. Epub 2009 Jul 28.

10.

Site-specific polysialylation of an antitumor single-chain Fv fragment.

Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Wright M, Chester KA, Deonarain MP.

Bioconjug Chem. 2009 May 20;20(5):924-31. doi: 10.1021/bc8005122.

PMID:
19402707
11.

Single-chain Fv phage display propensity exhibits strong positive correlation with overall expression levels.

Scott N, Reynolds CB, Wright MJ, Qazi O, Fairweather N, Deonarain MP.

BMC Biotechnol. 2008 Dec 29;8:97. doi: 10.1186/1472-6750-8-97.

12.

Recombinant antibodies for cancer therapy.

Deonarain MP.

Expert Opin Biol Ther. 2008 Aug;8(8):1123-41. doi: 10.1517/14712598.8.8.1123 . Review.

PMID:
18613764
13.

Modulation of antibody pharmacokinetics by chemical polysialylation.

Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Deonarain MP.

Bioconjug Chem. 2008 Mar;19(3):643-50. doi: 10.1021/bc700319r. Epub 2008 Feb 29.

PMID:
18307285
14.

Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments.

Bhatti M, Yahioglu G, Milgrom LR, Garcia-Maya M, Chester KA, Deonarain MP.

Int J Cancer. 2008 Mar 1;122(5):1155-63. Erratum in: Int J Cancer. 2008 Jul 1;123(1):245.

15.

Phage display of chelating recombinant antibody libraries.

Wright MJ, Deonarain MP.

Mol Immunol. 2007 Apr;44(11):2860-9. Epub 2007 Mar 13.

PMID:
17353051
16.

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.

Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP.

Br J Cancer. 2005 Nov 28;93(11):1257-66.

17.

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM.

Br J Cancer. 2004 May 4;90(9):1863-70.

18.

Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells.

Kousparou CA, Epenetos AA, Deonarain MP.

Int J Cancer. 2002 May 1;99(1):138-48.

19.

A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I.

Linardou H, Epenetos AA, Deonarain MP.

Int J Cancer. 2000 May 15;86(4):561-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk